Aclarion’s Market Position: Analyzing Performance Against Competitors

Aclarion, Inc. (NASDAQ: ACON) has emerged as a notable player in the “Medical Services” sector, which comprises 93 publicly traded companies. A recent financial survey provides insight into how Aclarion compares to its competitors across various key metrics, including institutional ownership, profitability, valuation, risk, and analyst recommendations.

Volatility and Risk Assessment

Aclarion’s stock exhibits a beta of **1.42**, indicating that it is **42% more volatile** than the S&P 500. In contrast, its competitors in the medical services industry show a higher average volatility with a beta of **1.53**, suggesting an overall **53% greater price fluctuation** compared to the S&P 500. This higher beta among competitors may reflect a more aggressive risk profile in their stock performance.

Earnings and valuation are crucial indicators of a company’s financial health. Aclarion’s gross revenue and earnings per share (EPS) have been compared with those of its rivals, showcasing a detailed analysis of its standing in the market.

Profitability and Ownership Insights

In terms of profitability, Aclarion’s performance metrics such as net margins, return on equity, and return on assets reveal how well it manages its resources in comparison to its peers. Currently, **7.5%** of Aclarion’s shares are owned by institutional investors, significantly lower than the **58.1%** average for the broader medical services sector. Insider ownership at Aclarion stands at **0.8%**, while competitors average **13.2%**. This disparity suggests that larger investment entities and insiders have less confidence in Aclarion’s long-term growth potential.

Analysts have provided Aclarion with a consensus price target of **$11,758.50**, indicating a remarkable potential upside of **190,784.74%**. This potential far surpasses the average upside of **15.45%** for other companies in the medical services industry. This significant difference suggests that market analysts view Aclarion as a more favorable investment opportunity compared to its competitors.

In summary, Aclarion’s competitors outperform it in **11 out of 13** key factors assessed in the analysis. Despite this, strong analyst support and a favorable price target may signal a potential turnaround for the company.

About Aclarion

Founded in **2008** and headquartered in **Broomfield, Colorado**, Aclarion, Inc. specializes in healthcare technology, particularly in Magnetic Resonance Spectroscopy (MRS). The company has developed a suite of software applications under the NOCISCAN brand. This includes **NOCICALC**, which processes raw MRS exam data into final spectra and identifies degenerative pain biomarkers, and **NOCIGRAM**, a clinical decision support tool. Aclarion was previously known as Nocimed, Inc. before rebranding in **December 2021**.

Investors and analysts continue to monitor Aclarion’s developments closely, as the company navigates its position in a competitive industry. For those interested in Aclarion and its peers, MarketBeat offers a daily summary of news and ratings to keep stakeholders informed.